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Community-associated methicillin-resistant Staphylo-
coccus aureus (MRSA) is the most common pathogen
among patients with skin and soft tissue infections seeking
treatment at a Los Angeles (USA) area emergency depart-
ment. The proportion caused by MRSA increased from
29% in 2001 to 2002 to 64% in 2003 to 2004. No clinical or
historical features reliably predict MRSA etiology.
H
istorically, methicillin-resistant Staphylococcus
aureus (MRSA) infection was associated with
patients in hospitals and skilled nursing facilities. In recent
years, reports of community-associated MRSA infections
(CA-MRSA) have been increasing (1,2). Such outbreaks
have been associated with prisons, intravenous drug use,
athletic teams, and men who have sex with men (1,2). CA-
MRSAhas primarily been described in skin and soft tissue
infections (SSTIs), but the agent has also been associated
with severe sepsis and pneumonia, primarily in pediatric
patients (3,4). Recent studies have described an increasing
proportion of MRSAisolates that are community-associat-
ed compared to hospital-associated isolates (5), but we are
not aware of any published studies reporting the preva-
lence of CA-MRSA among patients with sporadic SSTI.
The proportion of SSTIs that are caused by CA-MRSAhas
important implications for empiric antimicrobial therapy.
The Study
We participated in several clinical trials of antimicro-
bial drugs for SSTI for which cultures were obtained from
all enrolled patients. This opportunity made it possible for
us to determine the prevalence of CA-MRSA among a
group of emergency department patients with SSTIs. This
report describes the proportion of emergency department
patients with community-acquired SSTIs due to MRSA.
The study was performed in a county-owned hospital in
the Los Angeles, California (USA) area, which serves a
largely uninsured, low-income population. More than
43,000 persons are treated in the emergency department
each year. At the hospital, we have participated in a num-
ber of clinical trials of various antimicrobial agents for
treating SSTIs. All patients enrolled in these studies had
cultures obtained from the infected site. Eligibility criteria
for the studies included age >18 and an SSTI with purulent
material available for culture. One study included patients
with uncomplicated infections that were suitable for outpa-
tient treatment with oral agents. Patients were also enrolled
in 3 studies of complicated infections for which the treat-
ing physicians believed admission for intravenous antimi-
crobial drugs was indicated. Patients were excluded if they
had previously received antimicrobial drugs for the infec-
tion, unless antimicrobial drugs had been taken for >72
hours with treatment failure. Patients were also excluded if
they had simple abscesses that did not require antimicro-
bial agents, if they had severe infections involving bone or
joint, or if they required amputation of an affected limb. 
Specimens were obtained from the site of infection and
transported by using sterile Dacron swabs. Specimens
were processed and cultured with standard techniques (6).
S. aureus was identified by colony morphologic features,
coagulase tests, and catalase tests. MICs were determined
by VITEK, GPS 106 or 109 card (bioMérieux, Durham,
NC, USA), according to manufacturer’s instructions. MIC
breakpoints and quality control protocols were used
according to standards established by NCCLS (7).
Clinical data were prospectively collected as part of the
clinical trials. In mid-2002, we began prospectively col-
lecting information on recent jail exposure. Those patients
enrolled previously were contacted by telephone, if possi-
ble, to obtain information on jail exposure. This study was
approved by the Olive View–UCLA institutional review
board. 
From January 2002 through December 2002, a total of
24 patients were enrolled in an outpatient antimicrobial
drug study. From August 2001 through March 2004, we
enrolled 72 patients in 3 inpatient studies, and each had
only 1 site of infection. Patients were 20–60 years of age,
with a median age of 42. Men made up 77% of the study
group. None of the patients resided in long-term care facil-
ities, and none of the infections was believed to be hospi-
tal-acquired.
MRSA was isolated from 44 (46%) of 96 patients (8
outpatients, 36 admitted). The proportion of infections
yielding MRSA increased from 14 (29%) of 49 during
2001 to 2002 to 30 (64%) of 47 from January 2003 through
March 2004. Other pathogens isolated included the follow-
ing: 15 methicillin-susceptible S. aureus, 19 Streptococcus
spp., 4 coagulase-negative staphylococci, 2 diphtheroids;
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sp. No organism was isolated from 7 patients.
Among 44 MRSA patients, 6 had been hospitalized
within the last year. None had indwelling catheters or other
recognized risk factors for MRSA. Five had diabetes; oth-
erwise, none had a notable associated coexisting illness.
Fifteen had previously received oral antimicrobial drugs
for the current infection, but treatment was unsuccessful.
Nine had recently used injected illegal drugs. Nine were
homeless. Of 36 MRSApatients for whom the information
was available, 3 had been in Los Angeles County Jail with-
in the last year, where an MRSA outbreak was recently
described (2).Most patients had no apparent epidemiolog-
ic risk factors associated with recent CA-MRSAoutbreaks.
No clinical or epidemiologic features were predictive of an
MRSA cause (Table).
Antimicrobial susceptibilities of the 44 MRSA isolates
were as follows: clindamycin 98%, erythromycin 2%, lev-
ofloxacin 16% (64% had intermediate susceptibility to lev-
ofloxacin), rifampin 98%, tetracycline 82%,
trimethoprim/sulfamethoxazole 100%. Fourteen of our
MRSA isolates from early 2003 were tested in the labora-
tory at the Los Angeles County Department of Health
Services. The isolates were found by pulsed-field gel elec-
trophoresis to be identical to the strain associated with the
outbreak at the Los Angeles County Jail, which belongs to
the USA300 ST:8 group (8,9). None of the 14 isolates test-
ed had inducible clindamycin resistance by the D test. 
Conclusions 
Our report demonstrates that the proportion of patients
with community-acquired SSTI caused by MRSA is
increasing, and CA-MRSAis now the most common cause
of community-acquired SSTIs at our center. Other reports
have suggested that CA-MRSA is becoming more com-
mon in other geographic areas in the United States and
Europe (10,11). A high proportion of CA-MRSA strains
(such as the USA300 ST:8 strain) have been found to carry
the Panton-Valentine leukocidin gene, which has been
associated with SSTI and necrotizing pneumonia (9,12).
We have noted anecdotally that many patients with CA-
MRSA exhibit a spontaneous abscess or furunculosis that
the patient thinks was caused by a spider bite.
The bacterial causes of common community-acquired
SSTIs are generally gram-positive organisms such as S.
aureus and Streptococcus pyogenes. Because of the pre-
dictable etiology of these infections, most physicians do
not routinely obtain cultures from these patients. Obtaining
cultures of SSTIs is now of greater importance to monitor
the extent of CA-MRSA infections in one’s community
and guide therapy in areas in which CA-MRSA is already
prevalent.
Most community-acquired SSTIs are treated with
antimicrobial drugs such as cephalexin and dicloxacillin.
Patients requiring intravenous therapy are most commonly
given agents such as cefazolin or oxacillin. In areas with a
high prevalence of CA-MRSA, empiric treatment for
SSTIs with β-lactam agents such as cephalexin or
dicloxacillin may no longer be appropriate. Oral agents
such as clindamycin or trimethoprim/sulfamethoxazole
and rifampin should be considered for CA-MRSA.
Although inducible clindamycin resistance was not found
in the few patients we tested, clinical failure due to
inducible clindamycin resistance among CA-MRSA has
been reported (13). Whether the addition of rifampin to
trimethoprim/sulfamethoxazole improves outcomes in
SSTI is not clear, but this combination appears to be more
effective in eradicating MRSA colonization (14).
Macrolides, tetracycline, and fluoroquinolones have
inconsistent activity against the MRSA isolates identified
in our study and other reports of CA-MRSA (11). For
severe infections treated in the inpatient setting, clin-
damycin or vancomycin should be included as part of
empiric therapy. 
Adequate drainage and débridement of SSTIs are
important in treatment. We did not find a higher rate of
MRSA among those patients in whom previous antimicro-
bial drug treatment had been unsuccessful and believe
inadequate drainage was the reason. 
Whether additional measures to eliminate carriage of
MRSA in these patients or their close household contacts
would be of any benefit is not known. Chlorhexidine body
washes and nasal mupirocin would be reasonable meas-
ures for those with recurrent SSTI or close contacts with
similar infections (15).
Our report has several limitations. One of the criteria
for study enrollment was availability of purulent material
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cellulitis without a purulent exudate are not represented in
our study sample. We did not culture every possible SSTI
seen at the emergency department, but we believe the
patients enrolled in these studies reflect the general popu-
lation with culturable SSTIs. All samples cultured during
2003 to 2004 were from patients with infections that
required hospital admission, so these results may not
reflect those patients with minor infections suitable for
outpatient treatment. Prevalence of CA-MRSA can vary
considerably between geographic areas, and our facility
may not be typical of southern California or other areas.
MRSAmay now be the most common pathogen among
patients with community-associated SSTIs in some areas.
Physicians should consider obtaining cultures in these
patients. In areas with a high prevalence of CA-MRSA,
empiric therapy for SSTIs with agents such as clindamycin
or trimethoprim/sulfamethoxazole and rifampin would be
appropriate.
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